Table 3. Meta-analysis of the subgroup including studies of stages I and II NSCLC with their characteristics.
|
Group of NSCLC: stages I–II (n=8) | |||||||
|---|---|---|---|---|---|---|---|
| Study | Method | Threshold | QS (%) | N Pts | Bcl-2+ (%) | HR | 95% CI |
| Apolinario et al (1997) | IHC-clone 100 | NM | 59 | 73 | 51 | 0.40 | 0.16–0.98 |
| Chen et al (1999) | IHC-clone 124 | NM | 33 | 40 | 43 | 0.18 | 0.04–0.88 |
| D'Amico et al (1999) | IHC-clone 120 | >50 | 72 | 408 | 23 | 0.88 | 0.60–1.28 |
| Higashiyama et al (1997) | IHC-clone 124 | >10 | 52 | 38 | 39 | 0.30 | 0.06–1.62 |
| Koukourakis et al (1997) | IHC-clone 100 | NM | 58 | 107 | 19 | 0.32 | 0.13–0.86 |
| Ohsaki et al (1996) | IHC-clone 124 | >20 | 50 | 45 | 29 | 0.45 | 0.13–1.56 |
| Pastorino et al (1997) | IHC-clone 120 | >10 | 76 | 485 | 17 | 0.89 | 0.65–1.21 |
| Pezzella et al (1993) | IHC-clone 100 | NM | 65 | 115 | 22 | 0.54 | 0.29–1.03 |
| Overall (fixed-effects model) | 1311 | 23 | 0.70 | 0.57–0.86 | |||
| Overall (random-effects model) | 0.59 | 0.42–0.83 | |||||
| χ2 statistic for heterogeneity=12.80, 7 df, P=0.08 | |||||||
IHC-clone 100=immunohistochemistry with monoclonal antibody 100; IHC-clone 124=immunohistochemistry with monoclonal antibody 124; QS=Median quality score; N pts=number of patients; Bcl-2+=presence of Bcl-2; df=degree of freedom; HR=hazard ratio; CI=confidence interval; NM=not clearly mentioned.